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AbstrAct:
Human chromosome 8p23 is a region that has the most frequent heterozygosity in 
common human adult epithelial malignancies, but its major tumor suppressor gene(s) 
remain to be identified. Telomerase is activated in most human cancers and is critical 
for cancer cell growth. However, little is known about the significance of telomerase 
activation in chromosome instability and cancer initiation. The gene encoding the 
potent and highly conserved endogenous telomerase inhibitor PinX1 is located at 
human chromosome 8p23. However, the role of PinX1 in telomerase regulation and 
cancer development is not clear. Recent works from our group indicate that PinX1 
is critical for maintaining telomere length at the optimal length. Furthermore, PinX1 
is reduced in a large subset of human breast cancer tissues and cells. Significantly, 
PinX1 inhibition activates telomerase, and elongates telomeres, eventually leading 
to chromosome instability, all of which are abrogated by telomerase knockdown 
or  knockout.  Moreover,  PinX1  allele  loss  causes  majority  of  mice  to  develop  a 
variety of epithelial cancers, which display chromosome instability and recapitulate 
to 8p23 allele loss in humans. These results indicate that PinX1 is a sought-after 
major tumor suppressor at human chromosome 8p23 that is essential for regulating 
telomerase activity and maintaining chromosome stability. These results suggest that 
inhibition of telomerase using PinX1 especially its telomerase inhibitory fragment 
or other methods might be used to treat cancers that have telomerase activation.
cHrOMOsOME 8P23 AND HUMAN 
cANcErs 
Inactivation of tumor suppressor genes due to gene 
alterations, notably loss of heterozygosity (LOH), plays 
a major role in the development of common human adult 
cancers [1, 2], with breast cancer as a good example [3-
8]. Chromosome 8p23 is one of the most frequent LOH 
regions in common human adult epithelial malignancies, 
including breast, liver, lung, and gastrointestinal cancers 
[9-26]. For example, up to 70% of hepatocellular 
carcinomas [9-14] and 60% of human gastric cancer 
[26] exhibit LOH at 8p23 near the maker D8S277. 8p23 
is also a common integration site for hepatitis B virus 
(HBV), a well-known major risk factor in liver cancer 
[10, 27]. Similarly, LOH on 8p is found in up to 50% of 
breast carcinomas and is often associated with advanced 
tumor stage and aggressive histology [15-19]. Although 
several potential tumor suppressors have been mapped to 
this region, including Nkx3.1 at 8p21 and FEZ1/LZTS1 
at 8p22 [21, 28-30], even the combined rates of loss of 
these genes could not account for the extensive alterations 
seen in human tumors [21], indicating that major tumor 
suppressor gene(s) remain to be identified. 
tElOMErAsE ActivAtiON AND 
cANcEr
Maintaining optimal telomere length is crucial for 
cells since excessive telomere loss leads to telomere 
fusions, anaphase bridges, aberrant mitotic chromosome 
separation  and  aneuploidy  [31-34].  Significantly,  these 
telomere dysfunction phenotypes are very common in 
human cancer, especially epithelial cancers [34-38]. Oncotarget 2011; 2:  810 - 819 811 www.impactjournals.com/oncotarget
Moreover, long-term lack of telomerase in mice leads 
to telomere shortening and dysfunction, and promotes 
oncogenesis in a certain condition such as lack of tumor 
suppressors p53 [34, 39-43] or DNA mismatch repair 
protein MSH2 [44] or in the presence of telomeric repeat 
binding factor TRF2 overexpression [45], and also shifts 
the tumor spectrum of p53 mutant mice to include more 
epithelial cancers [42]. Thus, telomere dysfunction 
caused by excessive telomere loss has been proposed 
as a major cause of chromosome instability in epithelial 
carcinogenesis [35, 38, 42]. 
However, it has been well documented that telomere 
shortening due to knockout of telomerase activates DNA 
damage pathways, limits cell proliferation and inhibits 
tumorigenesis in a number of mouse models [46-50]. 
Moreover, although telomere loss in cancers has well 
documented, telomere elongation is quite common in a 
variety of epithelial cancers, e.g. in >40% of liver cancer 
[51], esophageal cancer [52] and brain tumors [53], and 
also correlates with advanced stages and/or poor survival 
in some cancers [51, 52, 54-57]. Even longer telomeres in 
blood cells are shown to be associated with higher cancer 
risk and poor survival in breast cancer [58]. However, 
little is known about the consequence of aberrant telomere 
elongation.
In mammalian cells, telomere surveillance is carried 
out in cis by shelterins, which include three telomeric 
DNA-binding proteins TRF1, TRF2 and POT1, and 
their associating proteins [59]. While TRF2 [32, 60] and 
POT1 [60-62] protect telomere integrity, TRF1 maintains 
telomeres at the optimal length [32, 59, 63]. Indeed, 
many TRF1-interacting or associated proteins influence 
telomere length [63-67]. We identified TRF1 as Pin2 in the 
same screen for Pin1 [68, 69]. Both Pin1 and Pin2/TRF1 
are important for mitotic regulation [69-73] and Pin1 
directly regulates TRF1 function in telomere maintenance 
and aging [74]. By identifying new TRF1/Pin2-interacting 
proteins, including PinX1-4, we have further identified 
important TRF1 function in telomere maintenance and 
mitosis [66, 74-76]. 
PiNX1 is A tElOMErAsE iNHibitOr 
EssENtiAl FOr MAiNtAiNiNG 
tElOMErAsE ActivitY AND 
tElOMErE lENGtH
Unlike other TRF1-interacting proteins, PinX1 has 
a unique property to directly bind to TERT and TERC 
and inhibit telomerase activity at telomere [66, 77] . 
Furthermore, PinX1 inhibition in cancer cells activates 
telomerase and elongates telomeres, whereas PinX1 
overexpression has the opposite effects [66]. The ability 
of PinX1 to regulate telomerase and telomere length is 
also  conserved  in  yeast,  rats  and  fish  [78-80].  In  fact, 
yeast PinX1 has been shown to inhibit telomerase by 
sequestering its protein catalytic subunit in an inactive 
complex lacking telomerase RNA in the nucleolus [78]. 
However, it was not clear why such telomerase inhibitor 
is needed until recently [81, 82].
By performing the extensive structure-function 
analysis  to  define  the  PinX1-TRF1  interaction  and 
to dissect the biological function of the PinX1-TRF1 
interaction in regulating telomere maintenance, we have 
demonstrated that the TRF1-PinX1 interaction is required 
not only for targeting PinX1 to telomeres, but also for 
PinX1 to prevent abnormal telomere elongation in cells 
[81]. Given the unique and potent ability of PinX1 to 
inhibit telomerase activity and telomere elongation in 
cells [66, 83], our results suggest that the TRF1-PinX1 
interaction affects the loading of PinX1 onto telomeres 
to prevent telomere elongation [81]. This may provide an 
additional level of telomerase regulation, in conjunction to 
the physical occlusion from telomeres by Pot1 [67, 84], by 
supplying a link between TRF1 and telomerase inhibition 
that contributes toward maintaining telomere homeostasis 
(Fig. 1). TRF1 binds along the duplex part of the telomere 
and functions as a measuring device to assess telomere 
Figure 1: the role of PinX1 in maintaining telomeres 
at the optimal length.  When telomerase extends a telomere 
to a certain length, the elongated telomere binds more TRF1, 
which might in turn recruit more PinX1 to the telomere. Once 
concentrated locally on telomeres at a high concentration, 
simple mass-action might allow PinX1 to more effectively 
stop telomerase from adding more repeats. Conversely, when a 
telomere is shortened following each cell division due to the end 
replication problem, the shortened telomere contains less TRF1, 
which might recruit fewer PinX1 or none at all to the telomere. 
Therefore, the telomere might have a greater chance of being 
elongated due to telomerase being inhibited less, or even not at 
all.  This Pinx1-mediated negative feedback mechanism might 
help maintain telomeres at a similar median length. (Adapted 
from Soohoo,et al., 2011, J Biol Chem 286:3894-3906).Oncotarget 2011; 2:  810 - 819 812 www.impactjournals.com/oncotarget
length [59, 63, 85, 86]. For telomere length homeostasis 
to be effective, the information about the length of the 
telomere needs to be relayed from TRF1 to telomerase 
via other proteins since TRF1 does not directly affect 
telomerase activity [59, 63]. Our data indicate that the 
telomerase inhibitor PinX1 might be recruited by TRF1 
to a telomere to stop telomerase action as the telomere is 
being elongated and reaches a certain threshold [81]. 
This model (Fig. 1) has been recently supported by 
manipulating PinX1 expression in vitro and in vivo to 
demonstrate that PinX1 is a rate-limiting physiological 
regulator of telomerase and telomere length [82]. We 
have shown that reduced PinX1 expression activates 
telomerase and leads to telomere lengthening and 
chromosome instability, which can be fully rescued 
by  TERT  knockdown  or  knockout  [82],  confirming 
that PinX1 acts as a telomerase inhibitor to regulate 
telomere maintenance. The significance of these results 
is demonstrated by our observations that most PinX1+/- 
mice develop aggressive cancers that display telomere 
lengthening and chromosome instability [82]. These 
results provide the first evidence for an essential role of 
PinX1 in regulating telomerase activity and telomere 
length [82]. 
PiNX1 is A sOUGHt-AFtEr MAJOr 
tUMOr sUPPrEssOr At 8P23 
EssENtiAl FOr cHrOMOsOME 
stAbilitY 
Notably, PinX1 gene localizes to human chromosome 
8p23 [13, 66], which is one of the regions that experiences 
the most frequent loss of heterozygosity (LOH) in many 
common human cancers [9, 10, 12, 15, 19, 21, 25, 26]. 
For example, 8p23 LOH has been found in up to 70% 
of hepatocellular carcinomas [9, 10, 12, 13], 60% of 
gastric cancer [26], and 50% of breast cancer [15, 19]. 
This region is also a common integration site for hepatitis 
B virus, a well-known major risk factor in liver cancer 
[10] and PinX1 is reduced in ~ 40% hepatitis B virus-
related liver cancer [13]. Moreover, PinX1 inhibition 
potently increases, whereas PinX1 overexpression 
suppresses, tumorigenicity of cancer cells [66]. Thus, 
PinX1 might be a putative tumor suppressor. Subsequent 
PinX1 studies on human cancer samples are inconclusive 
[26, 87]. Moreover, there is no genetic evidence for any 
involvement of PinX1 in cancer. 
The recent results from my laboratory indicate that 
PinX1 is a major tumor suppressor at 8p23 [82]. PinX1 is 
downregulated in a large subset of human breast cancer 
tissues and in most breast cancer cell lines examined [82]. 
PinX1 expression is gene dosage-dependent; ablation of 
one allele reduces protein level by 60-70% in vitro and 
in vivo. Importantly, reducing PinX1 by gene knockout 
or knockdown not only increases telomerase activity and 
telomere length, but also leads to chromosome instability 
in cell models [82]. These telomere-related phenotypes are 
fully reversed by knockout or knockdown of telomerase. 
Moreover, telomere lengthening induced by PinX1 
Figure 2: PinX1 as a sought-after major 
haploinsufficient  tumor  suppressor  at  8p23  that  is 
essential  for  chromosome  stability.  The human PinX1 
gene is located at 8p23, a frequent LOH in common human 
epithelial cancers and its protein expression is often down-
regulated in many human cancer tissues and cell lines. While 
PinX1 null mice or cells are lethal, reducing PinX1 expression 
via heterozygous knockout or knockdown increases telomerase 
activity and leads to telomere lengthening, anaphase bridges, 
chromosome translocation and instability, as shown in the 
picture. Moreover, PinX1 heterozygous knockout causes most 
mice to spontaneously develop a range of malignant tumors 
displaying evidence of telomere lengthening and chromosomal 
instability. Notably, the majority of cancers in the PinX1 mutant 
mice are carcinomas and share tissues of origin with human 
cancer types linked to 8p23 alterations.  Furthermore, many 
PinX1 heterozygous knockout mice develop more than one 
type of tumor and diverse histopathologies are observed in the 
same types of tumors among different mice or even in the same 
tumors, as shown for lung cancer. (Adapted from Zhou,et al., 
2011, J Clin Invest 121:1266-1282)Oncotarget 2011; 2:  810 - 819 813 www.impactjournals.com/oncotarget
inhibition occurs at most chromosome ends, a feature 
of cancer cells [88]. The significance of these findings is 
further substantiated by the demonstrations that nearly all 
PinX1+/- mice develop a range of epithelial malignancies 
with evidence of telomere lengthening and chromosome 
instability.
Although most human cancers are epithelial 
carcinomas, common tumor suppressor mutant mice 
mainly develop lymphomas and soft tissue sarcomas, with 
a very few exceptions [89, 90]. Notably, most tumors in 
PinX1+/- mice are epithelial carcinomas arising in organs 
that are known to develop common cancers in humans, 
including lung, mammary, liver and gastrointestinal tract 
cancers [82], which are also known to have frequent LOH 
at 8p23 in humans [9, 10, 12, 20-22, 24, 25]. Most tumors 
showed features commonly seen in advanced human 
carcinomas such as nuclear atypia, desmoplasia, stromal 
invasion and/or lung metastasis [82]. Moreover, 20% 
of PinX1+/- mice developed two or three cancer types 
within the same animals. Even within one tumor type, 
there were diverse histopathologies in different mice, the 
same mice or even within the same tumors [82]. Thus, 
almost all PinX1+/- mice spontaneously develop a range 
of aggressive epithelial cancers [82], which are unusual in 
mice, even after deleting many other tumor suppressors 
[89, 90], but are known to have 8p23 LOH in humans. 
These results suggest that PinX1+/- cancers likely 
originate from multiple cells and behave aggressively. 
Given activation of telomerase in most human cancers 
and common downregulation of PinX1 in liver, gastric 
and breast cancers [13, 26, 82], these results indicate that 
PinX1 is a major tumor suppressor, whose downregulation 
activates telomerase, induces chromosome instability and 
eventually leads to tumorigenesis by [82].
HOW DOEs PiNX1 rEGUlAtE 
cHrOMOsOME stAbilitY AND 
tUMOriGENEsis?
At the present time, we do not yet know the molecular 
mechanism by which reducing PinX1 function leads to 
chromosome instability and tumorigenesis. Notably, we 
have shown that the PinX1 knockout phenotypes including 
telomerase activation, telomere elongation, anaphase 
bridges, aneuploidy and chromosome instability are fully 
suppressed by knockdown or knockout of TERT or TERC, 
indicating that telomerase is essential for PinX1 reduction 
to induce chromosome instability [82]. Moreover, it 
takes time for PinX1-induced telomerase activation to 
induce telomere elongation and chromosome instability 
when PinX1 is knocked out or down [82]. Notably, the 
PinX1 and p53 double mutant mice have similar tumor 
spectrum [82] that are found in TERC and p53 double 
mutant mice due to telomere loss [42] or in TPP1/ACD 
and p53 double mutant mice due to telomere deprotection 
[91]. Furthermore, abnormal telomere elongation is 
common and also correlates with advanced stages and/or 
poor survival in some cancers [51, 52, 54, 57]. Moreover, 
TERC is required for the tumor-promoting effects of TERT 
overexpression in transgenic mice [92]. These results 
together suggest that abnormal telomerase activation and 
telomere lengthening due to loss of PinX1 might have 
similar effects on the development of epithelial cancers, 
as does telomere shortening or telomere deprotection. 
Given that PinX1 directly binds to and inhibits TERT [66] 
and is targeted by TRF1 to telomeres to prevent abnormal 
telomere elongation by telomerase [93], it is conceivable 
that when PinX1 is inhibited, telomerase is aberrantly 
activated without a proper brake and eventually leads to 
chromosome instability possibly via inducing aberrant 
telomere elongation to compromise telomere function [82]. 
Consistent with this idea is the previous findings that loss 
of p80/p95 in Tetrahymena induces telomere lengthening 
and chromosome instability [94]. However, telomerase 
has other telomere-independent function such as in DNA 
damage response [95, 96] and activating β-catenin [97]. 
Similarly, PinX1 might have non-telomeric functions 
such as in RNA maturation [98] and cell division [99]. 
Moreover, it has been shown that TERT overexpression 
extends life span in normal human cells in vitro [100-
102] and that short-term telomerase reactivation reverses 
tissue  degeneration  in  aged  telomerase-deficient  mice 
[103], although long-term TERT overexpression promotes 
tumorigenesis in vitro or in vivo [92, 104-110]. These 
results suggest that long-term loss of PinX1 function and/
or telomerase overexpression might affect other cellular 
processes that contribute to chromosome instability and 
tumorigenesis. Therefore, further experiments are needed 
to define how PinX1 controls chromosome stability via 
telomere-dependent and/or -independent telomerase and/
or other mechanisms unrelated to telomerase [82]. 
Although it is not clear how PinX1 downregulation 
leads to chromosome instability, we have demonstrated 
that PinX1-induced chromosome instability plays a 
major and novel role in tumorigenesis [82]. We show that 
PinX1 is reduced in most human breast cancer tissues and 
cells and that reducing PinX1 levels leads to telomerase 
activation, telomere elongation and chromosome 
instability [82]. Moreover, almost all PinX1 heterozygous 
knockout mice develop a range of epithelial malignancies, 
with multiple tumor types in the same mice, diverse cell 
morphologies/grades in one tumor type among mice, or 
even within individual tumors [82]. PinX1 heterozygous 
knockout also shifts the p53 mutant tumor spectrum to 
epithelial carcinomas [82]. Importantly, PinX1+/- cancer 
cells also display chromosome instability, similar to 
those in PinX1-inhibited cells [82]. Thus, PinX1 mutant 
tumors are likely derived from multiple epithelial cells, 
presumably due to chromosome instability. These results 
are  consistently  previous  findings  that  PinX1  potently 
controls tumorigenicity of cancer cells [66], and that 
telomerase overexpression promotes tumorigenesis, Oncotarget 2011; 2:  810 - 819 814 www.impactjournals.com/oncotarget
but is not as oncogenic as PinX1 knockout. Notably, 
telomerase activation and telomere lengthening induced 
by due to lack of PinX1 [82] and telomere dysfunction 
due to telomere shortening and deprotection share some 
common features including anaphase bridges, aneuploidy, 
translocation and chromosome instability both in MEFs 
and tumors. However, unlike the latter, the former induces 
chromosome instability in the presence of functional p53 
and the absence of TIF (telomere dysfunction-induced 
focus) [82]. These results suggest that downregulation of 
PinX1 induces chromosome instability and tumorigenesis 
without activating DNA damage pathways [82]. 
PiNX1 is AN AttrActivE NEW 
tArGEt iN cANcEr tHErAPY 
An increasing body of evidence suggests that 
PinX1 is an attractive new target in cancer therapy. We 
have originally shown that whereas reducing PinX1 
in human cancer cells increases their tumorigenicity, 
overexpression of PinX1, especially its small TID domain 
(telomerase-inhibitory domain) drives cancer cells into 
crisis and potently suppresses their ability to form tumors 
in mice [66]. These findings have now been confirmed 
and expanded to many different human cancer cells by 
transducing recombinant full length PinX1 protein or its 
protein fragments containing TID into cancer cells using 
HIV-Tat-mediated delivery [111] or mBAFF-targeted 
delivery [112]. Interestingly, overexpression of PinX1 
also enhances the sensitivity of human cancer cells to 
chemotherapy  drug  5-fluorouracil  [113].  Furthermore, 
human PinX1 is located to 8p23 [13, 66], a frequent 
LOH region in common human epithelial cells [9, 10, 
12, 15, 19, 21, 25, 26], and PinX1 protein is indeed 
downregulated commonly in many human epithelial 
cancers examined [13, 26, 66, 82]. Moreover, reducing 
PinX1 levels by heterozygous knockout or knockdown 
leads to chromosome instability and tumorigenesis in 
vitro and in vivo, with most tumors in PinX1+/- mice 
being carcinomas and sharing tissues of origin with 
human cancer types linked to 8p23 [82]. The therapeutic 
significance of these findings is further substantiated by 
the demonstration that the ability of PinX1 knockout or 
knockdown to induce chromosome instability is fully 
blocked by TERT knockout or knockdown [82]. Indeed, 
inhibition of telomerase by a wide range of approaches 
including chemical inhibitors or vaccines have been 
shown to potently inhibit cancer cell growth and even 
cancer stem cells in vitro, in vivo, with promising results 
in clinical trials [114, 115]. Therefore, these results 
together indicate that inhibition of telomerase by PinX1, 
especially its small telomerase inhibitory domain might 
be used to treat cancers that have telomerase activation. 
cONclUsiON AND FUtUrE 
DirEctiONs
Originally  identified  as  a  TRF1/Pin2-binding 
protein, PinX1 is a potent telomerase inhibitor. Recent 
results have not only demonstrated that PinX1 is 
essential for maintaining telomeres at the optimal length, 
but also discovered that Pinx1 is a sought-after major 
tumor suppressor at human chromosome 8p23 that is 
essential for maintaining chromosome stability in vitro 
and in vivo. Moreover, emerging evidence suggest that 
PinX1 and especially its small telomerase inhibitory 
domain might be a potential new drug target for treat 
cancers that have telomerase activation. However, many 
questions remained to be addressed including how PinX1 
regulates chromosome stability and tumorigenesis, how 
PinX1 is regulated under physiological and pathological 
conditions, how to develop PinX1-based cancer therapy, 
and whether PinX1 has other new functions. Further 
studies on this relatively unknown protein would uncover 
novel insight into the regulation of chromosome stability 
and tumorigenesis and might eventually lead to new 
therapies for cancers.
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